Skip to content
Review Open access

Metabolic shifts driven by host-microbial interactions

Sep 2026 · The FEBS Journal · 0 citations · 392 references
Medicine

TL;DR

This work focuses on microbial metabolism as a central organizing principle of host–microbiota symbiosis and discusses emerging therapeutic strategies that target microbial metabolic functions that position microbial metabolism as a tractable axis for modulating immunometabolism homeostasis and potentially mitigating metabolic and inflammatory diseases.

Abstract

Host–microbe interactions within the gut have been extensively reviewed in the context of host immune response. Emerging evidence, however, highlights that these inflammatory and immune outcomes are often deeply intertwined with the microbiome-derived secondary metabolites. The gut microbiota functions in concert with the host by providing an extensive repertoire of metabolic enzymes that enhance digestion and capacity to assimilate a broad spectrum of ingested food sources. This symbiotic metabolism generates a diverse array of bioactive metabolites that shape local and systemic physiology, adaptive immune responses, and neuroimmune responses. Here, we focus on microbial metabolism as a central organizing principle of host–microbiota symbiosis. Microbiota-derived metabolites, including short-chain fatty acids, secondary bile acids, tryptophan-derived indoles, sphingolipids, and gaseous byproducts, signal through downstream molecular partners like nuclear receptors, transcriptional regulators, and redox-sensitive homeostatic pathways to regulate host energy homeostasis, but also alter immune functions like gut epithelial integrity, immune tolerance, and neuro-immune crosstalk. Finally, we discuss emerging therapeutic strategies that target microbial metabolic functions - including dietary interventions, engineered probiotics, postbiotics, and receptor-directed approaches – that position microbial metabolism as a tractable axis for modulating immunometabolism homeostasis and potentially mitigating metabolic and inflammatory diseases.

Read PDF

Similar papers

Review Open access Aug 2026

Gut-microbiota-mediated host immune modulation: mechanisms, pathological dysbiosis, and therapeutic frontiers

The mammalian immune system has evolved in constant dialogue with its diverse microbiota, forming an ecological and molecular partnership that is fundamental to health. This review examines how microbial communities shape immunity across developmental and functional axes, the immunological consequences of dysbiosis dur...

P. Babu, V. Prakash, Suja Subhash et al. · 0 citations
Review Open access Aug 2026

Bacterial Extracellular Vesicles as Regulators of the Gut Microbiome–Circadian Axis in Inflammatory and Metabolic Diseases

Understanding the BEV–gut microbiome–circadian axis provides new mechanistic insights into host–microbe communication and highlights BEVs as promising postbiotic candidates for restoring immune–metabolic homeostasis and developing next-generation microbiome-targeted therapeutics.

Hyejin Choi, S. Oh, Young-Hun Kim · 0 citations
Review Open access Sep 2026

Interkingdom microbiome physiology in colorectal cancer: barrier dysfunction, immune-metabolic signaling, and therapeutic resistance

This review synthesizes evidence linking the bacteriome, mycobiome, and phageome to colorectal carcinogenesis, immune modulation, metabolic signaling, and therapeutic response and proposes that therapeutic resistance may sometimes reflect a treatment-selected ecological state rather than the action of a single resistan...

Shamim Pourbahrighesmat, Alireza Tojjari, G. Laliotis et al. · 0 citations
Review Sep 2026

Microbial Extracellular Vesicles of Gut Microbiome: Implication on therapeutic Strategies

This review consolidates current knowledge of MEV origins across kingdom boundaries, diverse biogenesis routes and conserved biology from prokaryotes to eukaryotes, along with the mechanistic pathways governing MEV uptake by host cells, to highlight the dualistic nature of MEVs.

D. Govindarajan, Viktoria Hentschel, T. Seufferlein · 0 citations
Review Open access Aug 2026

Signaling Metabolites in the Gut Microbiota–Organ Axes

It is predicted that clinical laboratories in the future will assay patient samples for an amalgamation of beneficial and detrimental microbiota metabolites as biomarkers of both health and disease risk.

Diren Beyoğlu, J. Idle · 0 citations
Review Aug 2026

Bifidobacterium and the gut-immune axis: Mechanistic insights and therapeutic potential.

Preclinical and clinical evidence suggests potential benefits in antibiotic-associated dysbiosis, inflammatory bowel disease, cancer therapy response, early life immune maturation, and selected metabolic and neuroimmune disorders, although the outcomes remain heterogeneous.

A. Ramesh, R. Subbarayan, Rupendra SHRESTHA et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.